Proven Intelligence in Preclinical Model Selection

The selection of an appropriate animal model is a foundational decision in the preclinical development of next-generation therapies. A standardized template does not exist; a data-driven strategy is required, tailored to the specific vector, payload, and target indication. This framework outlines the strategic considerations for employing rodent, nonhuman primate (NHP), and specialized models to build a robust data package for IND submissions to global regulatory bodies like the FDA and EMA, aligned with ICH guidelines. The objective is to generate translatable data that accurately predicts human response and minimizes clinical risk.

Frequently Asked Questions

Q: How do you determine whether to use rodent or nonhuman primate models for AAV toxicology studies?

The decision is driven by the scientific objective and vector biology. Rodent models are effective for initial proof-of-concept, dose-ranging, and evaluating non-target tissue biodistribution. Nonhuman primate (NHP) models are employed when assessing complex immune responses or when the vector’s tropism and receptor binding do not translate to lower-order species, providing data with higher fidelity to human clinical outcomes.

Q: What is the strategic value of using specialized humanized models in an IND-enabling program?

Specialized rodent models with humanized components are instrumental for evaluating therapies targeting human-specific genes or pathways. For instance, in developing a therapy for a genetic disorder like familial hypercholesterolemia, a model expressing the human LDLR gene allows for direct assessment of on-target efficacy, generating data that supports the therapeutic hypothesis for regulatory review.

Q: How is animal model selection aligned with global regulatory expectations from agencies like the FDA and EMA?

A unified strategy is designed from the outset to meet harmonized international guidelines (ICH). By selecting models that provide data acceptable to multiple regulatory bodies, we help sponsors build a single, comprehensive data package suitable for multi-jurisdictional IND or IMPD submissions. This approach streamlines the path to global clinical trials.

A Framework for Preclinical Model Selection

The preclinical evaluation of next-generation therapies requires a nuanced approach to animal model selection. The biological activity of a viral vector like AAV, or the delivery of an RNA payload via an LNP, is dictated by interactions with host-specific factors. Consequently, the choice of species is a determinant of data quality and its relevance to human safety and efficacy. Our scientific leadership, whose work contributed to a 100% successful IND rate since 2019, designs these programs based on first principles. Franklin Biolabs was formally launched in 2024, building upon this extensive track record.

Foundational Assessments in Rodent Models

Rodent models serve as a valuable initial platform for pharmacology and toxicology assessments. They are well-suited for:
* Early proof-of-concept and efficacy evaluations.
* Dose-range finding studies to establish preliminary toxicity thresholds.
* Characterizing vector biodistribution and transgene expression patterns across tissues.

These studies provide important data for vector optimization and initial risk assessment before committing to more complex models. They form the bedrock of a phased, data-driven preclinical strategy.

The Translational Bridge: Nonhuman Primate Models

For many next-generation therapies, particularly those involving AAV vectors, nonhuman primate (NHP) models offer the highest degree of biological translation to humans. The immunological and physiological similarities are indispensable for predicting clinical outcomes. The discovery of novel AAV serotypes from rhesus monkeys, such as AAV8, highlighted that NHP-derived vectors can possess favorable tropism and lower pre-existing seroprevalence in human populations, making the NHP the most relevant species for toxicology assessment (PMID: 12192090).

NHP models are selected to:
* Evaluate potential immunogenicity against the vector capsid or transgene product.
* Conduct IND-enabling toxicology studies under GLP conditions.
* Confirm biodistribution and expression profiles in a system that closely mirrors human anatomy and physiology.

Specialized Models for Targeted Indications

For therapies targeting human-specific genes or metabolic pathways, standard animal models may not be sufficient. In these cases, genetically modified or humanized models provide the necessary biological context. Demonstrating efficacy of an AAV8 vector in a specialized rodent model of familial hypercholesterolemia provided direct evidence of target engagement and therapeutic benefit, a powerful component of a future regulatory submission (PMID: 22985273). These specialized models are key to de-risking programs targeting specific genetic diseases.

Commitment to Animal Welfare and Program Integrity

All in vivo programs are conducted with a deep commitment to animal welfare, adhering to the 3Rs (Replacement, Reduction, and Refinement) and operating under AAALAC and USDA oversight. Our more than 100,000 square foot facility is designed for enhanced housing and enrichment, ensuring the integrity of our data and the ethical treatment of all animals. This commitment is a core component of our scientific operations. [FBL-VID-09]

Our approach ensures that every preclinical program is built on a solid scientific foundation, leveraging the most appropriate models to support an 18-24 month timeline to IND. This work is part of our broader mission within Preclinical and Translational Services.

---

---